![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration grants Elanco Animal Health an exclusive global rights to KIND-030, a monoclonal antibody targeting canine parvovirus. Under the agreement, KindredBio also has a right of last refusal to manufacture certain of Elanco's other monoclonal antibody products.
Lead Product(s): KIND-030
Therapeutic Area: Infections and Infectious Diseases Product Name: KIND-030
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Elanco
Deal Size: $16.5 million Upfront Cash: $0.5 million
Deal Type: Collaboration December 11, 2020